Document is current
Any future updates will be listed below
-
Authors
Yavari, Negin
Wai, Karen M.
Alsoudi, Amer F.
Koo, Euna
Ludwig, Chase A.
Kossler, Andrea L.
Nguyen, Quan Dong
Mruthyunjaya, Prithvi
Rahimy, Ehsan https://orcid.org/0000-0001-8446-7078
-
Funding
Funding for this research was provided by:
P30 Vision Research Core Grant (P30-EY026877)
Research to Prevent Blindness
National Eye Institute (1K12EY033745)
- License Information
-
More Information
Article History
Received: 4 August 2025
Revised: 4 August 2025
Accepted: 24 August 2025
First Online: 4 September 2025
Declarations
:
: This study only contained deidentified patient electronic medical records, therefore it was exempted from institutional review board approval.
: Not applicable.
: Not applicable.
: AK: Consultant–Immunovant, Genentech, Lassen, AmGen, Acelyrin. Independent Contracted Research Viridian Therapeutics. Sling Therapeutics, Kriya Therapeutics. QDN: Consultant–Genentech, Kriya Therapeutics, Regeneron. Research Support–Belite Bio, Genentech, Kriya Therapeutics, Priovant, Regeneron. PM: Consultant–Alcon, Amgen, Aura Biosciences, Castle Biosciences, Alcon, Genentech, Dutch Ophthalmic, Immunogen; Financial support– Genentech; Lecturer–Alcon. ER: Consultant–Apellis Pharmaceuticals, Iveric Bio, Genentech, Regeneron, Allergan, Zeiss, Google; Speaker–Apellis Pharmaceuticals, Genentech, Regeneron, Allergan. The other authors have disclosed no conflicts of interest.
